PARICAM P–3005 is an innovative anti-inflammatory drug, based on state-of-the-art Antisense-Technology and aimed to improve the common mechanical dental treatment against periodontitis in the human oral cavity. Until now there is no effective medical therapeutic agent dedicated to treat gum diseases including periodontitis available on the market.
PARICAM P-3005 therefore targets
an unmet medical need.
PARICAM P–3005 is a new investigational drug to revolutionize the treatment of human periodontitis in a sustainable mode of action based on 2nd generation Antisense-Oligonucleotide therapeutics. In combination with the development of a treatment-specific and disease-optimized thermogel formulation, this novel therapeutic approach addresses periodontal diseases and aims to improve the very high global burden for a sustainable and effective oral and dental health care system. With PARICAM P-3005 we present a realistic and unique approach for the treatment of periodontitis in humans by direct root cause control on genetic level of the chronic inflammation in the oral cavity.
Periodontitis is linked with various
Periodontitis is the major cause of tooth loss, but also linked to various severe diseases like heart diseases, diabetis, respiratory diseases, cancer, Alzheimer‘s disease and others.
Periodontitis is the 6th most prevalent disease worldwide.
In 2017 nearly 1 billion people were affected globally, which is expected to reach 2 billion people by 2050.
Successful treatment of periodontal disease can significantly reduce the financial impact on the overall health care system.
Standard Care situation:
Dentists work usually with manual mechanical techniques (root planning, scraping, etc.); mostly unpleasant, possibly painful, permanent repeat of treatment is necessary.
Local and systemic Antibiotics (e.g. Arestin®, Actise®, Ligosan®, Elyzol®, others) PerioChip® (Chlorhexidin Chip), Vector® (ultrasonic treatment), Laser treatment, GTR (guided tissue regeneration)
PARICAM P-3005 is a highly active molecular drug developed for the treatment of gingivitis and periodontitis in humans. Its clinical targets are acute and chronic inflammations in the human oral cavity. It is easy to administer and comes with a veritable mode of action. In contrast to other therapies not the bacterial infection is addressed, but the dysregulated immune response as root cause which will be cured by PARICAM P-3005.
Results of comparison:
None of the existing products are addressing the molecular basis of acute and chronical inflammations. All alternative drugs available are not long-lasting and the costs of a therapy are usually borne by patients themselves. The mechanical therapeutic method is state-of the art at dentists globally. Most innovative/alternative methods are cost extensive with undefined chance of success.